Breaking: EPO board to refer key issues in Broad appeal to higher panel

The European Patent Office (EPO) will refer several questions in the Broad Institute’s ongoing CRISPR patent case to the enlarged board of appeal, meaning the case is set to drag out further.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotechnology

A stricter interpretation: the EPO and antibodies

27 October 2020 Is the grant of a reasonable scope for antibody-related inventions at the European Patent Office a phenomenon of the past? Joachim Wachenfeld and Florian Grasser of Vossius & Partner report.

Europe

Breaking: EPO revokes Broad’s CRISPR patent

16 January 2020 In a dramatic reversal, a European Patent Office’s board of appeal has upheld the revocation of a Broad Institute CRISPR/Cas9 patent.

Europe

EPO launches ‘Fighting coronavirus’ data platform

6 July 2020 The European Patent Office has unveiled data sets relating to antiviral vaccines and pharmaceutical therapeutics as part of its new “Fighting coronavirus” platform.

More on this story

Europe

EPO launches ‘Fighting coronavirus’ data platform

6 July 2020 The European Patent Office has unveiled data sets relating to antiviral vaccines and pharmaceutical therapeutics as part of its new “Fighting coronavirus” platform.

Europe

Breaking: EPO revokes Broad’s CRISPR patent

16 January 2020 In a dramatic reversal, a European Patent Office’s board of appeal has upheld the revocation of a Broad Institute CRISPR/Cas9 patent.

Biotechnology

A stricter interpretation: the EPO and antibodies

More on this story

Europe

EPO launches ‘Fighting coronavirus’ data platform

6 July 2020 The European Patent Office has unveiled data sets relating to antiviral vaccines and pharmaceutical therapeutics as part of its new “Fighting coronavirus” platform.

Europe

Breaking: EPO revokes Broad’s CRISPR patent

16 January 2020 In a dramatic reversal, a European Patent Office’s board of appeal has upheld the revocation of a Broad Institute CRISPR/Cas9 patent.

Biotechnology

A stricter interpretation: the EPO and antibodies